Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderaterestriction

European Respiratory Journal

Volumn 46, Issue 5, 2015, Pages 1370-1377

  Raghu, Ganesh ^a,k   Nathan, Steven D ^b   Behr, Juergen ^c   Brown, Kevin K ^d   Egan, James J ^e   Kawut, Steven M ^f   Flaherty, Kevin R ^g   Martinez, Fernando J ^g   Wells, Athol U ^h   Shao, Lixin ⁱ   Zhou, Huafeng ⁱ   Henig, Noreen ⁱ   Szwarcberg, Javier ⁱ   Gillies, Hunter ⁱ   Montgomery, Alan B ^j   O'Riordan, Thomas G ⁱ  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b INOVA FAIRFAX HOSPITAL   (United States)

^c Fachklinik Gauting   (Germany)

^d DEPARTMENT OF MEDICINE   (United States)

^e MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^h ROYAL BROMPTON HOSPITAL   (United Kingdom)

ⁱ GILEAD SCIENCES   (United States)

^j Cardeas Pharma   (United States)

^k UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; PLACEBO; PHENYLPROPIONIC ACID DERIVATIVE; PYRIDAZINE DERIVATIVE;

ADULT; AGED; AIRWAY RESISTANCE; ARTICLE; COHORT ANALYSIS; EXERCISE; FEMALE; FIBROSING ALVEOLITIS; HEART CATHETERIZATION; HEART LEFT VENTRICLE FAILURE; HEART OUTPUT; HUMAN; LUNG ARTERY PRESSURE; LUNG DIFFUSION CAPACITY; LUNG GAS EXCHANGE; LUNG VOLUME; LUNG WEDGE PRESSURE; MAJOR CLINICAL STUDY; MALE; OXYGEN SATURATION; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL CAPACITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FAILURE; ARTERIAL PRESSURE; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; HEART LEFT VENTRICLE FUNCTION; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; WORLD HEALTH ORGANIZATION;

AGED; ARTERIAL PRESSURE; CARDIAC CATHETERIZATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION, PULMONARY; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MALE; MIDDLE AGED; PHENYLPROPIONATES; PULMONARY WEDGE PRESSURE; PYRIDAZINES; VENTRICULAR DYSFUNCTION, LEFT; WORLD HEALTH ORGANIZATION;

EID: 84946594045     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01537-2014     Document Type: Article

References (18)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
2. Shlobin OA, Nathan SD. Pulmonary hypertension secondary to interstitial lung disease. Expert Rev Respir Med 2011; 5: 179-189.
3. Seeger W, Adir Y, Barberà JA, et al. Pulmonary hypertension in chronic lung disease. J Am Coll Cardiol 2013; 62: D109-D116.
4. Rivera-Lebron BN, Forfia PR, Kreider M, et al. Echocardiographic and hemodynamic predictors of mortality in idiopathic pulmonary fibrosis. Chest 2013; 144: 564-570.
5. Lederer DJ, Borczuk AC, Kawut SM. Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest 2007; 132: 998-1006.
6. Corte TJ, Wort SJ, Wells AU. Pulmonary hypertension in idiopathic pulmonary fibrosis: a review. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26: 7-19.
7. Shorr AF, Wainright JL, Cors CS, et al. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J 2007; 30: 715-721.
8. Nathan SD, Shlobin OA, Ahmad S, et al. Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respiration 2008; 76: 288-294.
9. Raghu G, Behr J, Brown KK, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med 2013; 158: 641-649.
10. Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013; 62: Suppl. 25, D42-D50.
11. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161: 646-664.
12. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
13. Seeger W, Adir Y, Barberà JA, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 2013; 62: Suppl. 25, D109-D116.
14. Cohen J. Statistical Power Analysis for the Behavioral Sciences 2nd Edn. Hillsdale, Lawrence Erlbaum, 1988.
15. Mejía M, Carrillo G, Rojas-Serranfo J, et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest 2009; 136: 10-15.
16. Steen V, Thomas A, Medsger J. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003; 48: 516-522.
17. Chang B, Schachna L, White B, et al. Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol 2006; 33: 269-274.
18. Hyldgaard C, Hilberg O, Bendstrup E. How does comorbidity influence survival in idiopathic pulmonary fibrosis? Respir Med 2014; 108: 647-653.